Domov › Rakovina obličiek (renálny bunkový karcinóm) › Texas › Houston
Klinické štúdie Rakovina obličiek (renálny bunkový karcinóm) v meste Houston, TX
35 štúdií pre Rakovina obličiek (renálny bunkový karcinóm) hľadá účastníkov v zariadeniach v meste Houston a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Prebieha náborFáza 1
- NEO-811 Houston Site, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- UT MD Anderson Cancer Center, Houston
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Prebieha náborFáza 1/2
- University of Texas - MD Anderson Cancer Center, Houston
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Prebieha náborFáza 2
- UT MD Anderson Cancer Center, Houston
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Prebieha náborFáza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Prebieha náborFáza 1/2
- MD Anderson Cancer Center, Houston
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Prebieha náborFáza 2
- M D Anderson Cancer Center, Houston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Prebieha náborFáza 1/2
- Texas Oncology - Gulf Coast, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology - Gulf Coast, Houston
- a 1 ďalších
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Prebieha náborFáza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Prebieha náborFáza 1
- Md Anderson Cancer Center, Houston
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Prebieha náborFáza 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Methodist Willowbrook Hospital, Houston
- a 1 ďalších
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Prebieha náborFáza 2
- MD Anderson Cancer Center, Houston
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Prebieha náborFáza 2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Research Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Houston Methodist Hospital, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Prebieha náborFáza 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
Prebieha náborFáza 1
- The University of Texas M. D. Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Prebieha náborFáza 1
- MD Anderson Cancer Center, Houston
PET/MR for Characterization of Renal Masses (RMs)
Prebieha náborObservačná štúdia
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Prebieha náborFáza 1/2
- MD Anderson Cancer Center, Houston
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Prebieha náborFáza 1
- UT MD Anderson, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Prebieha náborFáza 1
- M D Anderson Cancer Center, Houston
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Prebieha náborFáza 1/2
- MD Anderson Cancer Center, Houston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Prebieha náborFáza 1
- MD Anderson Cancer Center, Houston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Prebieha náborFáza 1
- University of Texas MD Anderson Cancer Center /ID# 252004, Houston
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Prebieha náborFáza 2
- MD Anderson Cancer Center, Houston
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Prebieha náborFáza 2
- M D Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Prebieha náborFáza 1/2
- MD Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
Prebieha nábor
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Prebieha náborFáza 1/2
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
Prebieha náborFáza 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Prebieha náborFáza 1
- The University of Texas MD Anderson Cancer Center, Houston
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Prebieha náborFáza 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Prebieha náborFáza 2
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
Štúdie Rakovina obličiek (renálny bunkový karcinóm) v iných mestách
- New York City, NY27 štúdií
- Nashville, TN23 štúdií
- Dallas, TX23 štúdií
- St. Louis, MO23 štúdií
- Los Angeles, CA20 štúdií
- Boston, MA16 štúdií
- Baldwin Park, CA16 štúdií
- Philadelphia, PA15 štúdií
- Pittsburgh, PA15 štúdií
- Queens, NY15 štúdií
- Rochester, MN14 štúdií
- Cleveland, OH14 štúdií
Iné štúdie v Houston
- Nemalobunkový karcinóm pľúc145 štúdií
- Rakovina prsníka126 štúdií
- Rakovina (všetky typy)121 štúdií
- Metastatická rakovina104 štúdií
- Kolorektálny karcinóm102 štúdií
- Rakovina vaječníkov89 štúdií
- Akútna myeloidná leukémia85 štúdií
- Rakovina pľúc78 štúdií
- Rakovina prostaty76 štúdií
- Rakovina endometria68 štúdií
- Rakovina pankreasu61 štúdií
- Melanóm59 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.